Title of Invention	A METHOD FOR PRODUCING AN EXTRACT OF GINKGO BILOBA HAVING A REDUCED CONTENT OF 4'-O-METHYL PYRIDOXINE AND BIFLAVONES
Abstract	The present invention relates to an improved multi-slep method for preparing an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones, wherein the depletion is carried out by filtration over an adsorber resin and/or an ion exchanger and the substances to be removed are retained on the resin. The invention further relates to an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones, which is obtainable by the method according to the present invention, as well as to its use.

Title of Invention

A METHOD FOR PRODUCING AN EXTRACT OF GINKGO BILOBA HAVING A REDUCED CONTENT OF 4'-O-METHYL PYRIDOXINE AND BIFLAVONES

Abstract

The present invention relates to an improved multi-slep method for preparing an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones, wherein the depletion is carried out by filtration over an adsorber resin and/or an ion exchanger and the substances to be removed are retained on the resin. The invention further relates to an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones, which is obtainable by the method according to the present invention, as well as to its use.

Full Text	WO 2006/117169 PCT/EP2006/004029 - 1 - Improved method for preparing ginkgo extracts having a low content of 4'-O-methyl pyridoxine and/or biflavones The present invention relates to an improved multi-step method for preparing an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones, wherein the depletion is effected by filtration over an adsorber resin and/or an ion exchanger and the substances to be removed are retained on the resin. The invention further relates to an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones which is obtainable by the method according to the present invention, as well as to its use. Since decades, extracts from the leaves of ginkgo biloba are used as a medica- ment. They are currently used for the treatment of different kinds of dementia and symptoms thereof as well as cerebral and peripheral blood circulation disorders. Ingredients, the efficacy is associated with, are terpene lactones (ginkgolides A, B, C and bilobalide) as well as glycosides of flavones (quercetin, kaempferol and isorhamnetin). The leaves of ginkgo biloba also contain components which do not contribute to the desired efficacy, but which may be responsible for risks and side effects. In addition to unpolar plant ingredients such as ginkgolic acids, those components are 4'-O-methyl pyridoxine and biflavones. In a ginkgo extract, which is efficacious and at the same time as safe as possible and as low in side effects as possible, these compounds should thus not be present to the largest possible extent. 4'-O-methyl pyridoxine may cause symptoms of poisoning such as convulsive sei- zures and unconsciousness. Thus, this compound is also referred to as ginkgo- toxin. The biflavones contained in ginkgo exhibit an immunotoxic potential and may elicit contact allergies. These biflavones contained in ginkgo are predomi- nantly the compounds amentoflavone, bilobetin, ginkgetin, isoginkgetin and sciadopitysin. WO 2006/117169 PCT/EP2006/004029 -2- 4'-0-Methyl pyridoxine: Biflavones: Amentoflavone: R1 = R2 = R3 = H Bilobetin: R1 = R3 = H, R2 = OCH3 Ginkgetin: R3 = H1, R1 = R2 = OCH3 Isoginkgetin: R1 = H1, R2 = R3 = OCH3 Sciadopitysin: R1 = R2 = R3 = OCH3 Methods for depleting 4'-O-methyl pyridoxine and simultaneously biflavones as well as the extracts obtained are already described in EP 1 037 646 B1. Therein, 4'-O-methyl pyridoxine is retained using an acidic cation exchanger and the bifla- vones are adsorbed on activated carbon. Preferably these depletion steps are car- ried out after step f) of the method according to EP 1 037 646 B1 (page 3), i.e., after "treating the solution with a lead compound or an insoluble polyamide". The method of EP 1 037 646 B1 is based on the method originally described in DE 39 40 091 C2. WO 2006/117169 PCT/EP2006/004029 -3- In EP 1 037 646 B1 the depletion of the biflavones and 4'-O-methyl pyridoxine is carried out at a stage of the method (step f)), wherein relatively high contents of lead salts and ammonium salts are present such that an increased amount of ion exchanger has to be employed. Furthermore, the depletions of biflavones and 4'-O-methyl pyridoxine are de- scribed and claimed in combination only. However, depending on the limits to be possibly established in the future and in view of the requirement of as low a modi- fication of the extract composition as possible, it may be desirable to remove the biflavones or 4'-O-methyl pyridoxine only. Furthermore, the contents of less than 50 ppm of 4'-O-methyl pyridoxine and less than 100 ppm of biflavones which are aspired in EP 1 037 646 B1, are still com- paratively high. Since EP 1 037 646 B1 does not describe a comparative example, also the actual degree of depletion achieved in Examples 2 and 3 cannot be seen from this reference. Thus, it is the object underlying the present invention to provide a method for pre- paring ginkgo extracts having a low content of 4'-O-methyl pyridoxine and/or a low content of bioflavones which does not have the disadvantages indicated above and, in particular, • wherein well recyclable and/or very inexpensive adsorbents are employed, • which leads to contents of 4'-O-methyl pyridoxine of less than 20 ppm, pref- erably less than 10 ppm and particularly preferred less than 2 ppm and/or contents of biflavones of less than 20 ppm, preferably less than 10 ppm and particularly preferred less than 5 ppm and • which leads to extracts having preferred contents of flavonoides of 20 to 30% by weight (particularly preferred 22.0 to 27.0%), of terpene lactones of 4.5 to 8.5% by weight (particularly preferred 5.0 to 7.0%, preferably 2.8 to 3.4% ginkgolides A, B and C and 2.6 to 3.2% bilobalid) and of ginkgolic acids (5 ppm at the most), wherein said contents of flavonoids of 22.0 to 27.0%, of terpene lactones of 5.0 to 7.0% (2.8 to 3.4% thereof ginkgolides A, B and C WO 2006/117169 PCT/EP2006/004029 -4- and 2.6 to 3.2% thereof bilobalid) and of ginkgolic acids (5 ppm at the most) fulfil the requirements of the German Pharmacopoeia 2003 ("Deutsches Arzneibuch"; DAB). According to the DAB the flavonoids are determined in the form of quercetin, kaempferol and isorhamnetin after acidic hydrolysis and calculated as flavonoid glycosides. This object could be solved by separating the biflavones using adsorber resins and/or separating 4'-O-methyl pyridoxine via acidic ion exchangers. In order to produce the extracts according to the present invention, preferably the following method is carried out, wherein steps a) to i) as well as m) are essentially described already in DE 39 40 091 C2, the total disclosure content of which, in particular with respect to the details of the method, shall be incorporated into the present application by reference: a) extracting the leaves of ginkgo biloba (drug) at a temperature of 20-100°C, pref- erably 40-60°C, using water-containing acetone having a content of 20-90% by weight, a water-containing alkanol having 1 to 3 carbon atoms (methanol, ethanol, n-propanol and isopropanol) and a content of 20-90% by weight or anhydrous methanol, wherein the ratio drug : solvent amounts to 1:4 to 1:20, preferably 1:5 to 1:10, b) separating the organic solvent by evaporating the solvent to a content of 10% by weight at the most (preferably 5% by weight at the most), wherein water may be added during the final distillation steps, c) diluting the remaining aqueous solution with water to a solids content of 5 to 25% by weight (preferably 15 to 20% by weight), cooling the solution to a tem- perature below 25°C (preferably about 10 to 12°C) and allowing the remaining aqueous solution to stand until a precipitation is formed, d) treating the remaining aqueous solution with ammonium sulfate (preferably to a content of up to 40% by weight, particularly preferred 25 to 35% by weight) and subsequently extracting the solution at least once using methyl ethyl ketone or a WO 2006/117169 PCT/EP2006/004029 -5- mixture of methyl ethyl ketone and acetone (preferably in a ratio of 9:1 to 4:6, in particular 6:4), e) concentrating the extract obtained (preferably to a solids content of 50 to 70% by weight) and diluting the extract with a mixture of ethanol and water to obtain a solution containing 50% by weight water and 50% by weight ethanol and having a solids content of 10% by weight, f) treating the solution with a lead compound (preferably with lead acetate, lead hydroxide acetate, lead nitrate or an aqueous suspension of lead hydroxide) until a change in colour from brown to umber occurs, or an insoluble polyamide (pref- erably polyamide 6, polyamide 6,6 or crosslinked polyvinylpyrrolidone (polyvi- done)), g) extracting the filtered solution using an aliphatic or cycloaliphatic solvent having a boiling point of 60 to 100°C, h) concentrating the remaining aqueous-alcoholic solution, subsequently treating the solution with ammonium sulfate and extracting the solution with methyl ethyl ketone and ethanol, (the solution is preferably concentrated under reduced pres- sure to an ethanol content of about 5% at the most, added with ammonium sulfate to a content of 20% by weight and extracted with the solvent in a ratio of 8:2 to 5:5, preferably 6:4), i) concentrating the organic phase obtained to a solids content of 50 to 70% by weight, k) dissolving the concentrate in an aqueous alkanol having 1 to 3 carbon atoms and optionally filtering the product, I) filtration over an adsorber resin and/or an ion exchanger, wherein the sub- stances to be removed are retained on the resin and m) drying the concentrate (preferably at a maximum temperature of 60 to 80°C) under reduced pressure to obtain a dry extract having a water content of less than 5%. It is the advantage of the method according to the present invention that the de- pletion step is carried out at the end of the method. Thus, a smaller amount of the WO 2006/117169 PCT/EP2006/004029 -6- ion exchanger has to be employed and particularly low contents of 4'-O-methyl pyridoxine and/or biflavones are obtained. Preferred adsorber resins in step I) are resins based on optionally substituted sty- renes/divinylbenzenes such as Diaion HP-20, HP-21 or Sepabeads SP-207 and SP-850. Preferred ion exchangers are strongly acidic ion exchangers such as Merck I or Amberlite IR-120. The filtration optionally includes the usual rinsing us- ing further solvent. The aqueous alkanol in step k) is aqueous methanol, ethanol, n-propanol or isopropanol having a content of 20-90% by weight, respectively, preferably aqueous ethanol, a concentration of 40 to 60% by weight being particu- larly preferred. A subject of the present invention are extracts, in particular dry extracts, which are obtainable by the method according to the present invention and which exhibit the following contents: • less than 20 ppm, preferably less than 10 ppm and in particular less than 2 ppm 4'-O-methyl pyridoxine and/or • less than 20 ppm, preferably less than 10 ppm and in particular less than 5 ppm biflavones. Furthermore, subject of the present invention are extracts, in particular dry ex- tracts, which are obtainable by the method according to the present invention and which exhibit the following further contents: • 20 to 30% by weight, preferably 22.0 to 27.0% by weight flavonoids, • 4.5 to 8.5% by weight, preferably 5.0 to 7.0% by weight terpene lactones and • less than 10 ppm, preferably not more than 5 ppm ginkgolic acids. A further subject of the present invention are extracts, in particular dry extracts, which are obtainable by the method according to the present invention and which exhibit the following contents: WO 2006/117169 PCT/EP2006/004029 -7- • 20 to 30% by weight, preferably 22.0 to 27.0% by weight flavonoids, • 2.5 to 4.5% by weight ginkgolides A, B and C in total, preferably 2.8 to 3.4% by weight ginkgolides A, B and C in total, • 2.0 to 4.0% by weight, preferably 2.6 to 3.2% by weight bilobalide, • less than 10 ppm, preferably not more than 5 ppm ginkgolic acids and • less than 20 ppm, preferably less than 10 ppm, particularly preferred less than 2 ppm of 4'-O-methyl pyridoxine and/or • less than 20 ppm, preferably less than 10 ppm and particularly preferred less than 5 ppm of biflavones. According to the European Pharmacopoeia, dry extracts generally have a dry residue of at least 95% by weight. The extracts according to the present invention can be administered in the form of powders, granules, tablets, dragees (coated tablets) or capsules, preferably orally. In order to prepare tablets, the extract is mixed with suitable pharmaceutically ac- ceptable adjuvants such as lactose, cellulose, silicon dioxide, croscarmellose and magnesium stearate, and pressed into tablets which are optionally provided with a suitable coating, for example made of hydroxymethylcellulose, polyethyleneglycol, pigments (such as titanium dioxide, iron oxide) and talcum. The extract according to the present invention can also be filled into capsules, optionally under the addi- tion of adjuvants such as stabilizers, fillers and the like. The dosage is such that 10 to 2000 mg, preferably 50 to 1000 mg and particularly preferred 100 to 500 mg extract are administered per day. A further subject of the present invention are medicaments, food products and other preparations containing these extracts, optionally in combination with other substances such as active ingredients and/or pharmaceutically acceptable adju- vants. The term "food product" as used herein particularly refers to dietetic food products, dietary supplement products as well as medical food and dietary sup- plements. WO 2006/117169 PCT/EP2006/004029 -8- Examples Preparation of the extract solution used in Examples 1 and 2 as well as in Comparative Examples 1 and 2 Dried leaves of ginkgo biloba (drug) were extracted at a temperature of about 50°C using seven times their weight (w/w) (i.e. drug-solvent ratio is 1:7) made up of acetone/water 60/40 (w/w) (step a)). The organic solvent was largely separated from the extract (step b)) and the re- maining concentrated aqueous solution was diluted with water to a solids content of about 10% by weight. The solution was cooled to a temperature of about 12°C under agitation and the resulting precipitate was removed (step c)). About 30% by weight ammonium sulfate was added to the remaining aqueous solution and the solution formed was extracted using a mixture of methyl ethyl ke- tone and acetone in a ratio of 6:4 (step d)). The extract obtained was largely concentrated and the concentrate thus obtained was diluted with water and ethanol such that a solution containing 50% by weight water and 50% by weight ethanol at a solids content of about 10% by weight was obtained (step e)). The solution was filtered and the filtrate was added with an aqueous solution of lead hydroxide acetate (step f)). After a further filtration, the remaining aqueous alcoholic solution was extracted with heptane (step g)). Subsequently, the remaining aqueous alcoholic solution was concentrated under reduced pressure to an ethanol content of about 5% and ammonium sulfate was added such that a content of about 20% by weight based on the water content was achieved. WO 2006/117169 PCT/EP2006/004029 -9- The solution obtained was extracted using a mixture of methyl ethyl ketone and ethanol in a ratio of 6:4 (step h)). The resulting organic phase was largely concentrated (solids content of about 55% by weight) (step i)). Then the product was diluted with ethanol and water such that a solution having an ethanol content of about 75% and a solids content of about 15% was obtained (step k)). Example 1: Ginkgo extract having a reduced content of 4'-O-methyl pyridox- ine 1249 g of the extract solution obtained according to the preparation method de- scribed above was adjusted with water to an ethanol content of about 40% (w/w) and applied to 50 ml (corresponding to 0.28 ml/g of the dry extract) Amberiite IR- 120 (strongly acidic ion exchanger) (column: about 2 x 16.5 cm; flow: about 8 ml/min) (step I)), followed by rinsing with 200 ml of 50% ethanol (w/w). The result- ing solution was concentrated on a rotary evaporator and dried in vacuum at 50°C (stepm)): 179.4 g. As can be seen from the following table, a content of 4'-O-methyl pyridoxine of 0.4 ppm was achieved without essentially modifying the contents of ingredients which are relevant with respect to the efficacy. Comparative Example 1: Ginkgo extract without depletion according to step I) of the present invention 98.4 g of the extract solution employed in Example 1 were concentrated by evapo- ration and dried in vacuum at 50°C: 14.7 g. WO 2006/117169 PCT/EP2006/004029 - 10- Example 2a): Ginkgo extract having a reduced content of biflavones 500 g of the extract solution obtained according to the preparation method de- scribed above were adjusted with water to an ethanol content of about 40% (w/w) and applied to 400 ml (corresponding to 5.7 ml/g of the dry extract) Sepabeads SP-850 (adsorber resin) (column: about 4 x 32 cm; flow: about 8 ml/min) (step I)), followed by rinsing with about 2 I of 40% ethanol (w/w) in total. 10% of the result- ing solution (259.3 g) were concentrated on a rotary evaporator and freeze-dried (step m)): 6.92 g. The remaining 90% of the solution were employed in Example 2b). As can be seen from the following table, biflavone contents of less than 1 ppm were achieved, respectively, without essentially modifying the contents of ingredi- ents which are relevant with respect to the efficacy. Example 2b): Ginkgo extract having a reduced content of 4'-O-methyl pyri- doxine and biflavones 90% of the solution obtained in Example 2a) (2334.1 g) were applied to 25 ml (corresponding to 0.40 ml/g of the dry extract) Amberlite IR-120 (strongly acidic ion exchanger) (column: about 1.5 x 11 cm; flow: about 10 ml/min) (step I)), fol- lowed by rinsing with 100 ml of 40% ethanol (w/w). The resulting solution was concentrated on a rotary evaporator and freeze-dried (step m)): 61.67 g. As can be seen from the following table, a content of 4'-O-methyl pyridoxine of 0.4 ppm and contents of biflavones of less than 1 ppm were achieved, respec- tively, without essentially modifying the contents of ingredients that are relevant with respect to the efficacy. WO 2006/117169 PCT/EP2006/004029 - 11 - Comparative Example 2: Ginkgo extract without depletion according to step I) of the present invention 50 g of the extract solution employed in Example 2a) were concentrated by evapo- ration and freeze-dried: 7.05 g. Comparative Example 3: Ginkgo extract with biflavone depletion and 4'-O- methyl pyridoxine depletion after treatment with a lead compound (step f)) according to EP 1 037 646 B1 Dried leaves of ginkgo biloba (drug) were extracted at a temperature of about 50°C using seven times their weight (w/w) (i.e. drug-solvent ratio is 1:7) made up of acetone/water 60/40 (w/w). The organic solvent was largely separated from the extract and the remaining concentrated aqueous solution was diluted with water to a solids content of about 10% by weight, cooled to a temperature of about 12°C under agitation and the resulting precipitate was removed. About 30% by weight ammonium sulfate was added to the remaining aqueous solution and the solution formed was extracted using a mixture of methyl ethyl ke- tone and acetone in a ratio of 6:4. The extract obtained was largely concentrated and the concentrate thus obtained was diluted with water and ethanol such that a solution containing 50% by weight water and 50% by weight ethanol at a solids content of about 10% by weight was obtained. The solution was filtered, the filtrate was added with an aqueous solu- tion of lead hydroxide acetate and filtered again (step f)). 150 ml of the solution thus obtained (portion of dry extract: 7.1%; ethanol content: about 50%) were stirred with 2.5 g (corresponding to 0.17 g/g of the final product) active carbon for 30 minutes at room temperature. The filtrate was applied to a WO 2006/117169 PCT/EP2006/004029 -12- column with 4.2 ml (corresponding to 0.28 ml/g of the final product) strongly acidic cation exchanger (Merck I). The ion exchanger column was washed with 4 x 5 ml EtOH (50%). The combined eluates were extracted by shaking using 3 x 70 ml n-hexane. The ethanol/water phase was concentrated on a rotary evaporator and diluted with water to 100 g. The extract solution thus obtained was extracted with 1 x 40 ml, 2 x 30 ml and 1 x 20 ml of a mixture of methyl ethyl ketone:ethanol in a ratio of 3:2, wherein 15 g ammonium sulfate was added to achieve phase separation. The organic phase was stirred for 1 h at room temperature after adding 25 g am- monium sulfate. The undissolved ammonium sulfate as well as the aqueous phase formed were separated. The extract solution was concentrated on a rotary evaporator at 50°C and dried in vacuum at 60°C: 14.8 g. As can be seen from the following table, a 4'-O-methyl pyridoxine content of 52 ppm and a biflavone content of 31.3 ppm and, thus, significantly higher con- tents and inferior depletion results are achieved compared to Example 2b) accord- ing to the present invention. The determination of the contents of flavonoids, terpene lactones and ginkgolic acids listed in Table 1 was carried in accordance with the DAB. The quantitative determination of 4'-O-methyl pyridoxine was performed by means of HPLC and fluorescence detection after enrichment via Sep Pak Plus C18 car- tridges, followed by enrichment via Bond Elut LRC-SCX cartridges, wherein a Phenomenex Prodigy 5 μ ODS-3 HPLC column and a gradient of trifluoroacetic acid (pH 2): methanol = 9:1 (v/v) → methanol, were employed. The determination of the contents of the biflavones listed in Table 1 was per- formed by means of HPLC and UV detection at 340 nm via a Waters Nova Pak WO 2006/117169 PCT/EP2006/004029 - 13- C18 column using a gradient of water: acetonitrile of 9:1 (v/v) + 0.3% by volume phosphoric acid (85%) → acetonitrile + 0.3% by volume phosphoric acid. In each case, calibration was performed using reference substances having a high, defined purity grade. -15- 15406WO HA/jr Claims 1. Method for producing an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones, characterized by the following steps of the method: a) extracting leaves of ginkgo biloba using water-containing acetone, a water- containing alkanol having 1 to 3 carbon atoms or anhydrous methanol, b) separating the organic solvent by concentrating the solvent to a content of 10% by weight at the most, wherein water may be added during the final distillation steps, c) diluting the remaining aqueous solution with water to a solids content of 5 to 25% by weight, cooling to a temperature below 25°C and allowing to stand until a precipitate is formed, d) treating the remaining aqueous solution with ammonium sulfate and subsequently extracting at least once using methyl ethyl ketone or a mixture of methyl ethyl ketone and acetone, e) concentrating the extract obtained and diluting with an ethanol-water mixture to obtain a solution containing 50% by weight water and 50% by weight ethanol at a solids content of 10% by weight, f) treating the solution with a lead compound or an insoluble polyamide, g) extracting the filtered solution using an aliphatic or cycloaliphatic solvent having a boiling point of 60 to 100°C, h) concentrating the remaining aqueous-alcoholic solution, followed by treating with ammonium sulfate and extracting with methyl ethyl ketone and ethanol, i) concentrating the organic phase obtained to a solids content of 50 to 70% by weight, k) dissolving the concentrate in an aqueous alkanol having 1 to 3 carbon atoms and optionally filtering, I) filtration over an adsorber resin to reduce the content of biflavones and/or an ion exchanger to reduce the content of 4'-O-methyl pyridoxine, wherein the substances to be removed are retained on the resin and AMENDED SHEET -16- m) drying the concentrate at reduced pressure to obtain a dry extract having a water content of less than 5%. 2. Method according to claim 1, wherein the aqueous alkanol in step k) is aqueous ethanol. 3. Method according to claim 2, wherein the aqueous ethanol is ethanol having a content of 40 to 60% by weight. 4. Method according to any one of claims 1 to 3, wherein the adsorber resin in step I) is a resin based on optionally substituted styrenes/divinylbenzenes. 5. Method according to any one of claims 1 to 3, wherein the ion exchanger in step I) is a strongly acidic ion exchanger. 6. Extract from leaves of ginkgo biloba, characterized by having the following contents: • less than 10 ppm 4'-O-methyl pyridoxine and/or • less than 20 ppm biflavones selected from the group comprising amentoflavone, bilobetin, ginkgetin, isoginkgetin and sciadopitysin. 7. Extract according to claim 6, characterized by having a content of less than 2 ppm 4'-O-methyl pyridoxine. 8. Extract according to claim 6 or 7, characterized by having a content of less than 10 ppm biflavones. 9. Extract according to claim 6 or 7, characterized by having a content of less than 5 ppm biflavones. AMENDED SHEET -17- TO. Extract according to any of claims 6 to 9, characterized by having the following contents: • 20 to 30% by weight flavonoids, selected from the group comprising quercetin, kaempferol and isorhamnetin glycosides, • 4.5 to 8.5% by weight terpene lactones and • less than 10 ppm ginkgolic acids. 11. Extract according to any of claims 6 to 9, characterized by having the following contents: • 22.0 to 27.0 % by weight flavonoids, selected from the group comprising quercetin, kaempferol and isorhamnetin glycosides, • 5.0 to 7.0% by weight terpene lactones and • 5 ppm ginkgolic acids at the most. 12. Extract according to any of claims 6 to 9, characterized by having the following contents: • 22.0 to 27.0 % by weight flavonoids, selected from the group comprising quercetin, kaempferol and isorhamnetin glycosides, • 2.8 to 3.4% by weight ginkgolides A, B and C in total, • 2.6 to 3.2% by weight bilobalid and • 5 ppm ginkgolic acids at the most. 13. Use of an extract according to any one of claims 6 to 12 for the manufacture of a medicament, food product or other preparation for the treatment of dementia and symptoms thereof and/or cerebral or peripheral blood circulation disorders. 14. Medicament, food product or other preparation, characterized by a content of a ginkgo extract according to any one of claims 6 to 12. AMENDED SHEET The present invention relates to an improved multi-slep method for preparing an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones, wherein the depletion is carried out by filtration over an adsorber resin and/or an ion exchanger and the substances to be removed are retained on the resin. The invention further relates to an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones, which is obtainable by the method according to the present invention, as well as to its use.

Full Text

WO 2006/117169 PCT/EP2006/004029
- 1 -
Improved method for preparing ginkgo extracts having a low
content of 4'-O-methyl pyridoxine and/or biflavones
The present invention relates to an improved multi-step method for preparing an
extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine
and/or biflavones, wherein the depletion is effected by filtration over an adsorber
resin and/or an ion exchanger and the substances to be removed are retained on
the resin. The invention further relates to an extract from ginkgo biloba having a
reduced content of 4'-O-methyl pyridoxine and/or biflavones which is obtainable
by the method according to the present invention, as well as to its use.
Since decades, extracts from the leaves of ginkgo biloba are used as a medica-
ment. They are currently used for the treatment of different kinds of dementia and
symptoms thereof as well as cerebral and peripheral blood circulation disorders.
Ingredients, the efficacy is associated with, are terpene lactones (ginkgolides A, B,
C and bilobalide) as well as glycosides of flavones (quercetin, kaempferol and
isorhamnetin). The leaves of ginkgo biloba also contain components which do not
contribute to the desired efficacy, but which may be responsible for risks and side
effects. In addition to unpolar plant ingredients such as ginkgolic acids, those
components are 4'-O-methyl pyridoxine and biflavones. In a ginkgo extract, which
is efficacious and at the same time as safe as possible and as low in side effects
as possible, these compounds should thus not be present to the largest possible
extent.
4'-O-methyl pyridoxine may cause symptoms of poisoning such as convulsive sei-
zures and unconsciousness. Thus, this compound is also referred to as ginkgo-
toxin. The biflavones contained in ginkgo exhibit an immunotoxic potential and
may elicit contact allergies. These biflavones contained in ginkgo are predomi-
nantly the compounds amentoflavone, bilobetin, ginkgetin, isoginkgetin and
sciadopitysin.

WO 2006/117169 PCT/EP2006/004029
-2-
4'-0-Methyl pyridoxine:
Biflavones:
Amentoflavone: R1 = R2 = R3 = H
Bilobetin: R1 = R3 = H, R2 = OCH3
Ginkgetin: R3 = H1, R1 = R2 = OCH3
Isoginkgetin: R1 = H1, R2 = R3 = OCH3
Sciadopitysin: R1 = R2 = R3 = OCH3
Methods for depleting 4'-O-methyl pyridoxine and simultaneously biflavones as
well as the extracts obtained are already described in EP 1 037 646 B1. Therein,
4'-O-methyl pyridoxine is retained using an acidic cation exchanger and the bifla-
vones are adsorbed on activated carbon. Preferably these depletion steps are car-
ried out after step f) of the method according to EP 1 037 646 B1 (page 3), i.e.,
after "treating the solution with a lead compound or an insoluble polyamide". The
method of EP 1 037 646 B1 is based on the method originally described in
DE 39 40 091 C2.

WO 2006/117169 PCT/EP2006/004029
-3-
In EP 1 037 646 B1 the depletion of the biflavones and 4'-O-methyl pyridoxine is
carried out at a stage of the method (step f)), wherein relatively high contents of
lead salts and ammonium salts are present such that an increased amount of ion
exchanger has to be employed.
Furthermore, the depletions of biflavones and 4'-O-methyl pyridoxine are de-
scribed and claimed in combination only. However, depending on the limits to be
possibly established in the future and in view of the requirement of as low a modi-
fication of the extract composition as possible, it may be desirable to remove the
biflavones or 4'-O-methyl pyridoxine only.
Furthermore, the contents of less than 50 ppm of 4'-O-methyl pyridoxine and less
than 100 ppm of biflavones which are aspired in EP 1 037 646 B1, are still com-
paratively high. Since EP 1 037 646 B1 does not describe a comparative example,
also the actual degree of depletion achieved in Examples 2 and 3 cannot be seen
from this reference.
Thus, it is the object underlying the present invention to provide a method for pre-
paring ginkgo extracts having a low content of 4'-O-methyl pyridoxine and/or a low
content of bioflavones which does not have the disadvantages indicated above
and, in particular,
• wherein well recyclable and/or very inexpensive adsorbents are employed,
• which leads to contents of 4'-O-methyl pyridoxine of less than 20 ppm, pref-
erably less than 10 ppm and particularly preferred less than 2 ppm and/or
contents of biflavones of less than 20 ppm, preferably less than 10 ppm and
particularly preferred less than 5 ppm and
• which leads to extracts having preferred contents of flavonoides of 20 to 30%
by weight (particularly preferred 22.0 to 27.0%), of terpene lactones of 4.5 to
8.5% by weight (particularly preferred 5.0 to 7.0%, preferably 2.8 to 3.4%
ginkgolides A, B and C and 2.6 to 3.2% bilobalid) and of ginkgolic acids (5
ppm at the most), wherein said contents of flavonoids of 22.0 to 27.0%, of
terpene lactones of 5.0 to 7.0% (2.8 to 3.4% thereof ginkgolides A, B and C

WO 2006/117169 PCT/EP2006/004029
-4-
and 2.6 to 3.2% thereof bilobalid) and of ginkgolic acids (5 ppm at the most)
fulfil the requirements of the German Pharmacopoeia 2003 ("Deutsches
Arzneibuch"; DAB).
According to the DAB the flavonoids are determined in the form of quercetin,
kaempferol and isorhamnetin after acidic hydrolysis and calculated as flavonoid
glycosides.
This object could be solved by separating the biflavones using adsorber resins
and/or separating 4'-O-methyl pyridoxine via acidic ion exchangers.
In order to produce the extracts according to the present invention, preferably the
following method is carried out, wherein steps a) to i) as well as m) are essentially
described already in DE 39 40 091 C2, the total disclosure content of which, in
particular with respect to the details of the method, shall be incorporated into the
present application by reference:
a) extracting the leaves of ginkgo biloba (drug) at a temperature of 20-100°C, pref-
erably 40-60°C, using water-containing acetone having a content of 20-90% by
weight, a water-containing alkanol having 1 to 3 carbon atoms (methanol, ethanol,
n-propanol and isopropanol) and a content of 20-90% by weight or anhydrous
methanol, wherein the ratio drug : solvent amounts to 1:4 to 1:20, preferably 1:5 to
1:10,
b) separating the organic solvent by evaporating the solvent to a content of 10%
by weight at the most (preferably 5% by weight at the most), wherein water may
be added during the final distillation steps,
c) diluting the remaining aqueous solution with water to a solids content of 5 to
25% by weight (preferably 15 to 20% by weight), cooling the solution to a tem-
perature below 25°C (preferably about 10 to 12°C) and allowing the remaining
aqueous solution to stand until a precipitation is formed,
d) treating the remaining aqueous solution with ammonium sulfate (preferably to a
content of up to 40% by weight, particularly preferred 25 to 35% by weight) and
subsequently extracting the solution at least once using methyl ethyl ketone or a

WO 2006/117169 PCT/EP2006/004029
-5-
mixture of methyl ethyl ketone and acetone (preferably in a ratio of 9:1 to 4:6, in
particular 6:4),
e) concentrating the extract obtained (preferably to a solids content of 50 to 70%
by weight) and diluting the extract with a mixture of ethanol and water to obtain a
solution containing 50% by weight water and 50% by weight ethanol and having a
solids content of 10% by weight,
f) treating the solution with a lead compound (preferably with lead acetate, lead
hydroxide acetate, lead nitrate or an aqueous suspension of lead hydroxide) until
a change in colour from brown to umber occurs, or an insoluble polyamide (pref-
erably polyamide 6, polyamide 6,6 or crosslinked polyvinylpyrrolidone (polyvi-
done)),
g) extracting the filtered solution using an aliphatic or cycloaliphatic solvent having
a boiling point of 60 to 100°C,
h) concentrating the remaining aqueous-alcoholic solution, subsequently treating
the solution with ammonium sulfate and extracting the solution with methyl ethyl
ketone and ethanol, (the solution is preferably concentrated under reduced pres-
sure to an ethanol content of about 5% at the most, added with ammonium sulfate
to a content of 20% by weight and extracted with the solvent in a ratio of 8:2 to
5:5, preferably 6:4),
i) concentrating the organic phase obtained to a solids content of 50 to 70% by
weight,
k) dissolving the concentrate in an aqueous alkanol having 1 to 3 carbon atoms
and optionally filtering the product,
I) filtration over an adsorber resin and/or an ion exchanger, wherein the sub-
stances to be removed are retained on the resin and
m) drying the concentrate (preferably at a maximum temperature of 60 to 80°C)
under reduced pressure to obtain a dry extract having a water content of less than
5%.
It is the advantage of the method according to the present invention that the de-
pletion step is carried out at the end of the method. Thus, a smaller amount of the

WO 2006/117169 PCT/EP2006/004029
-6-
ion exchanger has to be employed and particularly low contents of 4'-O-methyl
pyridoxine and/or biflavones are obtained.
Preferred adsorber resins in step I) are resins based on optionally substituted sty-
renes/divinylbenzenes such as Diaion HP-20, HP-21 or Sepabeads SP-207 and
SP-850. Preferred ion exchangers are strongly acidic ion exchangers such as
Merck I or Amberlite IR-120. The filtration optionally includes the usual rinsing us-
ing further solvent. The aqueous alkanol in step k) is aqueous methanol, ethanol,
n-propanol or isopropanol having a content of 20-90% by weight, respectively,
preferably aqueous ethanol, a concentration of 40 to 60% by weight being particu-
larly preferred.
A subject of the present invention are extracts, in particular dry extracts, which are
obtainable by the method according to the present invention and which exhibit the
following contents:
• less than 20 ppm, preferably less than 10 ppm and in particular less than
2 ppm 4'-O-methyl pyridoxine and/or
• less than 20 ppm, preferably less than 10 ppm and in particular less than 5
ppm biflavones.
Furthermore, subject of the present invention are extracts, in particular dry ex-
tracts, which are obtainable by the method according to the present invention and
which exhibit the following further contents:
• 20 to 30% by weight, preferably 22.0 to 27.0% by weight flavonoids,
• 4.5 to 8.5% by weight, preferably 5.0 to 7.0% by weight terpene lactones and
• less than 10 ppm, preferably not more than 5 ppm ginkgolic acids.
A further subject of the present invention are extracts, in particular dry extracts,
which are obtainable by the method according to the present invention and which
exhibit the following contents:

WO 2006/117169 PCT/EP2006/004029
-7-
• 20 to 30% by weight, preferably 22.0 to 27.0% by weight flavonoids,
• 2.5 to 4.5% by weight ginkgolides A, B and C in total, preferably 2.8 to 3.4%
by weight ginkgolides A, B and C in total,
• 2.0 to 4.0% by weight, preferably 2.6 to 3.2% by weight bilobalide,
• less than 10 ppm, preferably not more than 5 ppm ginkgolic acids and
• less than 20 ppm, preferably less than 10 ppm, particularly preferred less
than 2 ppm of 4'-O-methyl pyridoxine and/or
• less than 20 ppm, preferably less than 10 ppm and particularly preferred less
than 5 ppm of biflavones.
According to the European Pharmacopoeia, dry extracts generally have a dry
residue of at least 95% by weight.
The extracts according to the present invention can be administered in the form of
powders, granules, tablets, dragees (coated tablets) or capsules, preferably orally.
In order to prepare tablets, the extract is mixed with suitable pharmaceutically ac-
ceptable adjuvants such as lactose, cellulose, silicon dioxide, croscarmellose and
magnesium stearate, and pressed into tablets which are optionally provided with a
suitable coating, for example made of hydroxymethylcellulose, polyethyleneglycol,
pigments (such as titanium dioxide, iron oxide) and talcum. The extract according
to the present invention can also be filled into capsules, optionally under the addi-
tion of adjuvants such as stabilizers, fillers and the like. The dosage is such that
10 to 2000 mg, preferably 50 to 1000 mg and particularly preferred 100 to 500 mg
extract are administered per day.
A further subject of the present invention are medicaments, food products and
other preparations containing these extracts, optionally in combination with other
substances such as active ingredients and/or pharmaceutically acceptable adju-
vants. The term "food product" as used herein particularly refers to dietetic food
products, dietary supplement products as well as medical food and dietary sup-
plements.

WO 2006/117169 PCT/EP2006/004029
-8-
Examples
Preparation of the extract solution used in Examples 1 and 2 as well as in
Comparative Examples 1 and 2
Dried leaves of ginkgo biloba (drug) were extracted at a temperature of about
50°C using seven times their weight (w/w) (i.e. drug-solvent ratio is 1:7) made up
of acetone/water 60/40 (w/w) (step a)).
The organic solvent was largely separated from the extract (step b)) and the re-
maining concentrated aqueous solution was diluted with water to a solids content
of about 10% by weight. The solution was cooled to a temperature of about 12°C
under agitation and the resulting precipitate was removed (step c)).
About 30% by weight ammonium sulfate was added to the remaining aqueous
solution and the solution formed was extracted using a mixture of methyl ethyl ke-
tone and acetone in a ratio of 6:4 (step d)).
The extract obtained was largely concentrated and the concentrate thus obtained
was diluted with water and ethanol such that a solution containing 50% by weight
water and 50% by weight ethanol at a solids content of about 10% by weight was
obtained (step e)). The solution was filtered and the filtrate was added with an
aqueous solution of lead hydroxide acetate (step f)).
After a further filtration, the remaining aqueous alcoholic solution was extracted
with heptane (step g)).
Subsequently, the remaining aqueous alcoholic solution was concentrated under
reduced pressure to an ethanol content of about 5% and ammonium sulfate was
added such that a content of about 20% by weight based on the water content
was achieved.

WO 2006/117169 PCT/EP2006/004029
-9-
The solution obtained was extracted using a mixture of methyl ethyl ketone and
ethanol in a ratio of 6:4 (step h)).
The resulting organic phase was largely concentrated (solids content of about
55% by weight) (step i)). Then the product was diluted with ethanol and water
such that a solution having an ethanol content of about 75% and a solids content
of about 15% was obtained (step k)).
Example 1: Ginkgo extract having a reduced content of 4'-O-methyl pyridox-
ine
1249 g of the extract solution obtained according to the preparation method de-
scribed above was adjusted with water to an ethanol content of about 40% (w/w)
and applied to 50 ml (corresponding to 0.28 ml/g of the dry extract) Amberiite IR-
120 (strongly acidic ion exchanger) (column: about 2 x 16.5 cm; flow: about 8
ml/min) (step I)), followed by rinsing with 200 ml of 50% ethanol (w/w). The result-
ing solution was concentrated on a rotary evaporator and dried in vacuum at 50°C
(stepm)): 179.4 g.
As can be seen from the following table, a content of 4'-O-methyl pyridoxine of
0.4 ppm was achieved without essentially modifying the contents of ingredients
which are relevant with respect to the efficacy.
Comparative Example 1: Ginkgo extract without depletion according to step
I) of the present invention
98.4 g of the extract solution employed in Example 1 were concentrated by evapo-
ration and dried in vacuum at 50°C: 14.7 g.

WO 2006/117169 PCT/EP2006/004029
- 10-
Example 2a): Ginkgo extract having a reduced content of biflavones
500 g of the extract solution obtained according to the preparation method de-
scribed above were adjusted with water to an ethanol content of about 40% (w/w)
and applied to 400 ml (corresponding to 5.7 ml/g of the dry extract) Sepabeads
SP-850 (adsorber resin) (column: about 4 x 32 cm; flow: about 8 ml/min) (step I)),
followed by rinsing with about 2 I of 40% ethanol (w/w) in total. 10% of the result-
ing solution (259.3 g) were concentrated on a rotary evaporator and freeze-dried
(step m)): 6.92 g. The remaining 90% of the solution were employed in Example
2b).
As can be seen from the following table, biflavone contents of less than 1 ppm
were achieved, respectively, without essentially modifying the contents of ingredi-
ents which are relevant with respect to the efficacy.
Example 2b): Ginkgo extract having a reduced content of 4'-O-methyl pyri-
doxine and biflavones
90% of the solution obtained in Example 2a) (2334.1 g) were applied to 25 ml
(corresponding to 0.40 ml/g of the dry extract) Amberlite IR-120 (strongly acidic
ion exchanger) (column: about 1.5 x 11 cm; flow: about 10 ml/min) (step I)), fol-
lowed by rinsing with 100 ml of 40% ethanol (w/w). The resulting solution was
concentrated on a rotary evaporator and freeze-dried (step m)): 61.67 g.
As can be seen from the following table, a content of 4'-O-methyl pyridoxine of
0.4 ppm and contents of biflavones of less than 1 ppm were achieved, respec-
tively, without essentially modifying the contents of ingredients that are relevant
with respect to the efficacy.

WO 2006/117169 PCT/EP2006/004029
- 11 -
Comparative Example 2: Ginkgo extract without depletion according to step
I) of the present invention
50 g of the extract solution employed in Example 2a) were concentrated by evapo-
ration and freeze-dried: 7.05 g.
Comparative Example 3: Ginkgo extract with biflavone depletion and 4'-O-
methyl pyridoxine depletion after treatment with a lead compound (step f))
according to EP 1 037 646 B1
Dried leaves of ginkgo biloba (drug) were extracted at a temperature of about
50°C using seven times their weight (w/w) (i.e. drug-solvent ratio is 1:7) made up
of acetone/water 60/40 (w/w).
The organic solvent was largely separated from the extract and the remaining
concentrated aqueous solution was diluted with water to a solids content of about
10% by weight, cooled to a temperature of about 12°C under agitation and the
resulting precipitate was removed.
About 30% by weight ammonium sulfate was added to the remaining aqueous
solution and the solution formed was extracted using a mixture of methyl ethyl ke-
tone and acetone in a ratio of 6:4.
The extract obtained was largely concentrated and the concentrate thus obtained
was diluted with water and ethanol such that a solution containing 50% by weight
water and 50% by weight ethanol at a solids content of about 10% by weight was
obtained. The solution was filtered, the filtrate was added with an aqueous solu-
tion of lead hydroxide acetate and filtered again (step f)).
150 ml of the solution thus obtained (portion of dry extract: 7.1%; ethanol content:
about 50%) were stirred with 2.5 g (corresponding to 0.17 g/g of the final product)
active carbon for 30 minutes at room temperature. The filtrate was applied to a

WO 2006/117169 PCT/EP2006/004029
-12-
column with 4.2 ml (corresponding to 0.28 ml/g of the final product) strongly acidic
cation exchanger (Merck I). The ion exchanger column was washed with 4 x 5 ml
EtOH (50%).
The combined eluates were extracted by shaking using 3 x 70 ml n-hexane. The
ethanol/water phase was concentrated on a rotary evaporator and diluted with
water to 100 g. The extract solution thus obtained was extracted with 1 x 40 ml,
2 x 30 ml and 1 x 20 ml of a mixture of methyl ethyl ketone:ethanol in a ratio of
3:2, wherein 15 g ammonium sulfate was added to achieve phase separation.
The organic phase was stirred for 1 h at room temperature after adding 25 g am-
monium sulfate. The undissolved ammonium sulfate as well as the aqueous
phase formed were separated. The extract solution was concentrated on a rotary
evaporator at 50°C and dried in vacuum at 60°C: 14.8 g.
As can be seen from the following table, a 4'-O-methyl pyridoxine content of
52 ppm and a biflavone content of 31.3 ppm and, thus, significantly higher con-
tents and inferior depletion results are achieved compared to Example 2b) accord-
ing to the present invention.
The determination of the contents of flavonoids, terpene lactones and ginkgolic
acids listed in Table 1 was carried in accordance with the DAB.
The quantitative determination of 4'-O-methyl pyridoxine was performed by means
of HPLC and fluorescence detection after enrichment via Sep Pak Plus C18 car-
tridges, followed by enrichment via Bond Elut LRC-SCX cartridges, wherein a
Phenomenex Prodigy 5 μ ODS-3 HPLC column and a gradient of trifluoroacetic
acid (pH 2): methanol = 9:1 (v/v) → methanol, were employed.
The determination of the contents of the biflavones listed in Table 1 was per-
formed by means of HPLC and UV detection at 340 nm via a Waters Nova Pak

WO 2006/117169 PCT/EP2006/004029
- 13-
C18 column using a gradient of water: acetonitrile of 9:1 (v/v) + 0.3% by volume
phosphoric acid (85%) → acetonitrile + 0.3% by volume phosphoric acid.
In each case, calibration was performed using reference substances having a
high, defined purity grade.

-15- 15406WO HA/jr
Claims
1. Method for producing an extract from ginkgo biloba having a reduced content of
4'-O-methyl pyridoxine and/or biflavones, characterized by the following steps of
the method:
a) extracting leaves of ginkgo biloba using water-containing acetone, a water-
containing alkanol having 1 to 3 carbon atoms or anhydrous methanol,
b) separating the organic solvent by concentrating the solvent to a content of
10% by weight at the most, wherein water may be added during the final
distillation steps,
c) diluting the remaining aqueous solution with water to a solids content of 5 to
25% by weight, cooling to a temperature below 25°C and allowing to stand until
a precipitate is formed,
d) treating the remaining aqueous solution with ammonium sulfate and
subsequently extracting at least once using methyl ethyl ketone or a mixture of
methyl ethyl ketone and acetone,
e) concentrating the extract obtained and diluting with an ethanol-water mixture
to obtain a solution containing 50% by weight water and 50% by weight ethanol
at a solids content of 10% by weight,
f) treating the solution with a lead compound or an insoluble polyamide,
g) extracting the filtered solution using an aliphatic or cycloaliphatic solvent
having a boiling point of 60 to 100°C,
h) concentrating the remaining aqueous-alcoholic solution, followed by treating
with ammonium sulfate and extracting with methyl ethyl ketone and ethanol,
i) concentrating the organic phase obtained to a solids content of 50 to 70% by
weight,
k) dissolving the concentrate in an aqueous alkanol having 1 to 3 carbon atoms
and optionally filtering,
I) filtration over an adsorber resin to reduce the content of biflavones and/or an
ion exchanger to reduce the content of 4'-O-methyl pyridoxine, wherein the
substances to be removed are retained on the resin and
AMENDED SHEET

-16-
m) drying the concentrate at reduced pressure to obtain a dry extract having a
water content of less than 5%.
2. Method according to claim 1, wherein the aqueous alkanol in step k) is aqueous
ethanol.
3. Method according to claim 2, wherein the aqueous ethanol is ethanol having a
content of 40 to 60% by weight.
4. Method according to any one of claims 1 to 3, wherein the adsorber resin in
step I) is a resin based on optionally substituted styrenes/divinylbenzenes.
5. Method according to any one of claims 1 to 3, wherein the ion exchanger in step
I) is a strongly acidic ion exchanger.
6. Extract from leaves of ginkgo biloba, characterized by having the following
contents:

• less than 10 ppm 4'-O-methyl pyridoxine and/or
• less than 20 ppm biflavones selected from the group comprising
amentoflavone, bilobetin, ginkgetin, isoginkgetin and sciadopitysin.

7. Extract according to claim 6, characterized by having a content of less than
2 ppm 4'-O-methyl pyridoxine.
8. Extract according to claim 6 or 7, characterized by having a content of less than
10 ppm biflavones.
9. Extract according to claim 6 or 7, characterized by having a content of less than
5 ppm biflavones.
AMENDED SHEET

-17-
TO. Extract according to any of claims 6 to 9, characterized by having the following
contents:
• 20 to 30% by weight flavonoids, selected from the group comprising
quercetin, kaempferol and isorhamnetin glycosides,
• 4.5 to 8.5% by weight terpene lactones and
• less than 10 ppm ginkgolic acids.
11. Extract according to any of claims 6 to 9, characterized by having the following
contents:
• 22.0 to 27.0 % by weight flavonoids, selected from the group comprising
quercetin, kaempferol and isorhamnetin glycosides,
• 5.0 to 7.0% by weight terpene lactones and
• 5 ppm ginkgolic acids at the most.
12. Extract according to any of claims 6 to 9, characterized by having the following
contents:
• 22.0 to 27.0 % by weight flavonoids, selected from the group comprising
quercetin, kaempferol and isorhamnetin glycosides,
• 2.8 to 3.4% by weight ginkgolides A, B and C in total,
• 2.6 to 3.2% by weight bilobalid and
• 5 ppm ginkgolic acids at the most.

13. Use of an extract according to any one of claims 6 to 12 for the manufacture of
a medicament, food product or other preparation for the treatment of dementia
and symptoms thereof and/or cerebral or peripheral blood circulation disorders.
14. Medicament, food product or other preparation, characterized by a content of a
ginkgo extract according to any one of claims 6 to 12.
AMENDED SHEET

The present invention relates to an improved multi-slep method for preparing an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones, wherein the depletion is carried out by filtration over an adsorber resin and/or an ion exchanger and the substances to be removed are retained on the resin. The invention further relates to an extract from ginkgo biloba having a reduced content of 4'-O-methyl pyridoxine and/or biflavones, which is obtainable by the method according to the present invention, as well as to its use.

Documents:

http://ipindiaonline.gov.in/patentsearch/GrantedSearch/viewdoc.aspx?id=hIoXLoPqi+BVrWA5QS/MaQ==&loc=wDBSZCsAt7zoiVrqcFJsRw==

« Previous Patent

Next Patent »

Patent Number

272655

Indian Patent Application Number

3893/KOLNP/2007

PG Journal Number

17/2016

Publication Date

22-Apr-2016

Grant Date

18-Apr-2016

Date of Filing

11-Oct-2007

Name of Patentee

DR. WILLMAR SCHWABE GMBH & CO. KG

Applicant Address

WILLMAR-SCHWABE-STRASSE 4 76227 KARLSRUHE

Inventors:

#	Inventor's Name	Inventor's Address
1	HAUER HERMANN	TROLLINGERSTR. 7,, 76228 KARLSRUHE
2	ERDELMEIER CLEMENS	GLOGAUER STR. 32,, 76139 KARLSRUHE
3	KOCH EGON	AM GIESSBACH 11A,, 76229 KARLSRUHE
4	LANG FRIEDRICH	BERWARTSTEINSTR. 18,, 76767 HAGENBACH

PCT International Classification Number

A61K 36/00

PCT International Application Number

PCT/EP2006/004029

PCT International Filing date

2006-04-28

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	102005061948.7	2005-12-23	Germany
2	102005020685.9	2005-05-03	Germany